Rapidly autopsied postmortem human brain and blood specimens from sporadic Alzheimer’s disease (AD), Autosomal Dominant AD, and Controls
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), has issued a Presolicitation Synopsis (Notice of Intent to Sole Source) to acquire rapidly autopsied postmortem human brain and blood specimens for Alzheimer's disease (AD) research. NIH intends to award a contract to Banner Health without full and open competition. Interested parties may submit capability statements by June 14, 2026, at 8:00 AM Eastern Time.
Purpose & Scope
The NIA requires these specialized specimens to identify and characterize molecular derangements in the AD process. The specimens must be sourced from sporadic AD, Autosomal Dominant AD, and control subjects.
Key Requirements
- Rapidly autopsied specimens with a postmortem interval of less than or equal to 3 hours.
- Minimal and uniform fixation of all specimens.
- Adequate numbers of both sporadic and autosomal dominant AD cases.
- Specimens available in both formalin-fixed paraffin embedded (FFPE) and frozen formats from the same cohort.
- Specimens must be robust enough to withstand harsh retrieval, stripping, and re-staining procedures.
Contract Details
This acquisition is conducted under FAR Part 13 (Simplified Acquisition Procedures) and is not expected to exceed the simplified acquisition threshold of $350,000. The contract will include provisions and clauses in effect through Federal Acquisition Circular (FAC) 2005-99-1. The NAICS code is 325414 (Drugs And Biologicals) with a size standard of 1,250 employees.
Submission & Response
This is not a request for competitive proposals. However, interested parties who believe they can meet the requirements may identify their interest and capability. Responses must include a technical proposal, cost-price proposal, proposed period of performance, Unique Entity ID (UEI), Taxpayer Identification Number (TIN), and certification of business size. All offerors must have an active registration in SAM.gov.
Responses must reference solicitation number PCA-NIA-05858 and be received electronically by June 14, 2026, at 8:00 AM Eastern Time. Submissions should be sent to Luz.Casey@nih.gov or Michael.falzone@nih.gov. Fax responses will not be accepted.
Eligibility & Set-Aside
This is a Sole Source acquisition; therefore, no set-aside applies. The government's determination not to compete is at its discretion.